Salim Syed
Stock Analyst at Mizuho
(2.40)
# 3,363
Out of 5,180 analysts
85
Total ratings
45.59%
Success rate
-0.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics | Maintains: Outperform | $12 → $10 | $1.40 | +614.29% | 1 | Mar 31, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Outperform | $45 → $43 | $23.83 | +80.44% | 1 | Mar 31, 2026 | |
| NKTX Nkarta | Maintains: Outperform | $14 → $12 | $2.22 | +441.76% | 9 | Mar 31, 2026 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $41 → $45 | $39.22 | +14.74% | 2 | Mar 25, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $22 → $27 | $7.27 | +271.39% | 6 | Mar 25, 2026 | |
| CYTK Cytokinetics | Maintains: Outperform | $84 → $100 | $67.50 | +48.15% | 8 | Mar 18, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $91 → $106 | $74.64 | +42.02% | 8 | Mar 18, 2026 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $97 | $30.49 | +218.19% | 1 | Mar 10, 2026 | |
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $94.79 | +27.65% | 1 | Dec 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $28.59 | +39.93% | 2 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $207 → $169 | $185.49 | -8.89% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $280 | $353.94 | -20.89% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $117 | $140.56 | -16.76% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $163 | $58.57 | +178.32% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $25 → $18 | $4.87 | +269.61% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $49.00 | +102.04% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.74 | +1,106.90% | 5 | Nov 16, 2022 |
Autolus Therapeutics
Mar 31, 2026
Maintains: Outperform
Price Target: $12 → $10
Current: $1.40
Upside: +614.29%
Syndax Pharmaceuticals
Mar 31, 2026
Maintains: Outperform
Price Target: $45 → $43
Current: $23.83
Upside: +80.44%
Nkarta
Mar 31, 2026
Maintains: Outperform
Price Target: $14 → $12
Current: $2.22
Upside: +441.76%
Enliven Therapeutics
Mar 25, 2026
Maintains: Outperform
Price Target: $41 → $45
Current: $39.22
Upside: +14.74%
Wave Life Sciences
Mar 25, 2026
Maintains: Outperform
Price Target: $22 → $27
Current: $7.27
Upside: +271.39%
Cytokinetics
Mar 18, 2026
Maintains: Outperform
Price Target: $84 → $100
Current: $67.50
Upside: +48.15%
BridgeBio Pharma
Mar 18, 2026
Maintains: Outperform
Price Target: $91 → $106
Current: $74.64
Upside: +42.02%
Maze Therapeutics
Mar 10, 2026
Initiates: Outperform
Price Target: $97
Current: $30.49
Upside: +218.19%
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $94.79
Upside: +27.65%
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $28.59
Upside: +39.93%
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $185.49
Upside: -8.89%
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $353.94
Upside: -20.89%
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $140.56
Upside: -16.76%
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $58.57
Upside: +178.32%
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $4.87
Upside: +269.61%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $49.00
Upside: +102.04%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.74
Upside: +1,106.90%